SCHEDULE 13D/A: RTW Investments Boosts Stake in Allurion Technologies to 17.6%

RTW Investments, LP and its affiliates have increased their beneficial ownership in Allurion Technologies, Inc. to 17.6% of the common stock outstanding.

Summary

• RTW Investments, LP, along with its managed funds RTW Master Fund, Ltd. and RTW Innovation Master Fund, Ltd., and its managing partner Roderick Wong, M.D., collectively hold a significant beneficial ownership in Allurion Technologies, Inc.
• As of February 20, 2025, the aggregate beneficial ownership reported by RTW Investments, LP and Roderick Wong, M.D. is 1,050,053 shares, representing 17.6% of Allurion's common stock.
• RTW Master Fund, Ltd. beneficially owns 501,806 shares, accounting for 8.4% of the class.
• RTW Innovation Master Fund, Ltd. beneficially owns 395,328 shares, accounting for 6.6% of the class.
• The beneficial ownership percentages are calculated based on 5,961,714 shares of Allurion Technologies, Inc. common stock outstanding, as disclosed in the Issuer's Prospectus Supplement filed on February 20, 2025.
• Notes held by the RTW Funds are subject to a beneficial ownership conversion limitation, preventing conversion if it would result in the RTW Funds and their affiliates owning more than 9.99% of the Issuer's shares.
• Warrants held by the RTW Funds are subject to a 'Blocker' currently set at 4.99%, which can be increased to 9.99% upon 61 days' prior notice by RTW.

Sentiment

Score: 7

Explanation: The filing indicates a substantial and continued investment by a prominent institutional investor, which is generally viewed positively as a sign of confidence in the company's value and future prospects.

Positives

• The significant stake held by RTW Investments, a specialized healthcare investor, indicates a strong vote of confidence in Allurion Technologies, Inc.'s long-term prospects.
• Increased institutional ownership can enhance market visibility and potentially attract further investor interest.

Risks

• The beneficial ownership conversion limitation of 9.99% on Notes held by RTW Funds restricts their immediate ability to convert these instruments into a larger equity stake.
• The 4.99% 'Blocker' on Warrants, while adjustable, similarly limits the immediate exercise of these warrants to increase ownership beyond a certain threshold without prior notice.

Future Outlook

The reporting persons have the ability to increase the 'Blocker' on their Warrants from 4.99% to 9.99% by providing 61 days' prior notice, which could allow for a greater exercise of warrants in the future.

Industry Context

This filing reflects a significant investment by a specialized healthcare fund in a medical technology company, indicating continued investor interest in the sector, particularly in companies like Allurion Technologies that operate in the weight-loss and obesity management space.

Comparison to Industry Standards

• Not applicable as this filing pertains to beneficial ownership percentages and does not contain performance metrics or industry comparisons of Allurion Technologies, Inc. against specific comparable companies or projects.

Stakeholder Impact

• Shareholders: The increased beneficial ownership by a major institutional investor may be perceived positively, potentially influencing investor sentiment and share price.
• Company Management: A significant institutional stake often leads to increased scrutiny and engagement from the investor regarding corporate strategy and governance.

Next Steps

• RTW has the option to increase the warrant 'Blocker' from 4.99% to 9.99% with 61 days' prior notice.

Key Dates

Keywords

Allurion Technologies, RTW Investments, Schedule 13D, Beneficial Ownership, Common Stock, Institutional Investment, Healthcare Technology, Medical Devices